Our ANS/inflammation-induced obesidome corroborates previous findings, yielding to future drug treatment focused on FOX1 and adrenergic regulation and revealing the beta-adrenergic receptor’s key role, whilst the stress-induced network evidences the role of asprosin and kisspeptin as drug candidates for obesity. This evidence concerns the gene RBFOX1 and obesity due to melanocortin 4 receptor deficiency.